KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials.

Laure Gossec, Andra Balanescu, Maria Antonietta D'Agostino, Alexis Ogdie, Philipp Sewerin, Yu Deng, Linyu Shi, Yoshiyuki Sugimoto, Sheng Zhong, Yunzhao Xing, Ralph Lippe, Mitsumasa Kishimoto

Arthritis Res Ther 28(1) 2

PMID41318485
PMCIDPMC12771703
DOI10.1186/s13075-025-03670-0
发表日期2025-11-29
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other;Fig. 3:AI 判定为 other。
摘要

摘要

BACKGROUND: The development of personalized approaches in psoriatic arthritis (PsA) is challenging due to unclear patient phenotypes and trajectories. Machine learning (ML) could help to identify homogeneous patient groups. The objective of this analysis was to classify patients with PsA into distinct phenotypes using ML. METHODS: A post hoc analysis of PsA patients treated with risankizumab for ≤ 4 years (196 weeks) from KEEPsAKE 1 and KEEPsAKE 2. The phenotypes were based on baseline demographics and clinical characteristics using unsupervised ML (a finite mixture model). Response to risankizumab at 4 years was defined as minimal disease activity (MDA) and Disease Activity in PsA (DAPSA) low disease activity (LDA). RESULTS: A total of 1119 patients were classified into 5 distinct PsA phenotypes: Moderate to High Disease Activity (40.3% of patients) - characterized by lower tender joint count (TJC) and swollen joint count (SJC), dactylitis, and enthesitis; Enthesitis and Large Joints Dominant (20.8% of patients) - characterized by enthesitis and mainly active large joints; Very High Disease Activity (14.0% of patients) - characterized by high TJC/SJC, dactylitis, and enthesitis; Hand Dominant (13.8% of patients) - characterized by active joints primarily in the hands; Dactylitis and Feet Dominant (11.1% of patients) - characterized by dactylitis and active joints primarily in the feet. At 4 years, risankizumab demonstrated efficacy across all phenotypes (MDA and DAPSA LDA; range: 42.9% to 58.8% of patients and 66.0% to 82.0% of patients, respectively), with highest responses observed in the Moderate to High Disease Activity and Dactylitis and Feet Dominant phenotypes. CONCLUSIONS: Five distinct PsA phenotypes were identified in patients starting risankizumab. Moderate to High Disease Activity, the most frequent phenotype, showed the highest response, though risankizumab demonstrated efficacy across all phenotypes. These results are a first step toward more personalized medicine for patients with PsA. TRIAL REGISTRATION: ClinicalTrials.gov: KEEPsAKE 1, NCT03675308; KEEPsAKE 2, NCT03671148.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Identified PsA Phenotypes Based on Frequency of Baseline Demographics and Clinical Characteristics. After exclusions, variables were defined as follows: dactylitis (number of joints affected by dactylitis, presence of dactylitis in hands, presence of dactylitis in feet), demographics (age, sex, BMI, smoking status, race, ethnicity, geographic region, work status), enthesitis (presence of enthesitis, SPARCC index score, location[s] of enthesitis), other (pain visual analog scale, FACIT-F score, CRP level, duration of PsA), psoriasis (skin involvement, location affected by psoriasis [head, lower extremities, trunk, upper extremities], psoriatic spondylitis), SJC (swollen joint involvement [by joint, yes/no], SJC66 [swollen joint count in 66 joints]), and TJC (tender joint involvement [by joint, yes/no], TJC68 [tender joint count in 68 joints]). BMI body mass index, CRP C-reactive protein, FACIT-F Functional Assessment of Chronic Illness Therapy - Fatigue, PsA psoriatic arthritis, SJC swollen joint count, SPARCC Spondyloarthritis Research Consortium of Canada, TJC tender joint count
非 KM Figure
Fig. 2Schematic of Identified PsA Phenotypes. PsA phenotypes identified using an unsupervised machine learning approach based on baseline demographics and clinical characteristics of PsA. BSA body surface area, PsA psoriatic arthritis
非 KM Figure
Fig. 3Efficacy Responses Across Psa Phenotypes Among BDMARD-Naïve Patients Receiving Continuous Risankizumab 150 mg (As Observed). Efficacy endpoints were analyzed using as observed data. a Analysis in patients with baseline HAQ-DI ≥ 0.35. b Analysis in patients with baseline pain VAS ≥ 10 mm. AO as observed, bDMARD biologic Disease-Modifying Antirheumatic Drug, CI confidence interval, DAPSA Disease Activity in Psoriatic Arthritis, HAQ-DI Health Assessment Questionnaire – Disability Index, LDA low disease activity, MCID minimal clinically important difference, MDA minimal disease activity, PsA psoriatic arthritis, SJC swollen joint count, TJC tender joint count, VAS visual analog scale
非 KM Figure